enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 50,600 shares, a decline of 93.4% from the November 30th total of 768,300 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 207,100 shares, the days-to-cover ratio is currently 0.2 days.

Insider Buying and Selling at enGene

In other enGene news, major shareholder Growth Opportunities F. Forbion acquired 10,153 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $6.37 per share, for a total transaction of $64,674.61. Following the transaction, the insider now owns 2,446,223 shares in the company, valued at $15,582,440.51. This trade represents a 0.42 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 369,326 shares of company stock valued at $2,345,518 in the last 90 days. 13.70% of the stock is currently owned by company insiders.

Institutional Trading of enGene

Institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. boosted its stake in enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after buying an additional 619,100 shares in the last quarter. SR One Capital Management LP bought a new stake in shares of enGene during the 2nd quarter valued at approximately $4,715,000. Logos Global Management LP increased its position in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares in the last quarter. Franklin Resources Inc. lifted its stake in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Finally, Wolverine Asset Management LLC acquired a new stake in enGene in the third quarter valued at approximately $37,000. Institutional investors own 64.16% of the company’s stock.

Analyst Ratings Changes

ENGN has been the topic of a number of recent research reports. Oppenheimer reissued an “outperform” rating and set a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and issued a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th. Raymond James initiated coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price target on the stock. Citizens Jmp upgraded enGene to a “strong-buy” rating in a report on Monday, November 18th. Finally, HC Wainwright started coverage on enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 target price on the stock. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $29.78.

enGene Stock Performance

enGene stock traded up $0.28 during mid-day trading on Friday, hitting $6.42. 67,687 shares of the company’s stock traded hands, compared to its average volume of 117,836. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The stock has a market cap of $283.87 million, a price-to-earnings ratio of -11.07 and a beta of -0.78. The firm has a 50 day simple moving average of $7.89 and a two-hundred day simple moving average of $7.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. On average, research analysts expect that enGene will post -1.52 EPS for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.